Skip to main content

BRVE · Braveheart Bio, Inc. · Shareholders & Ownership

Track BRVE — free
$21.69 +0.25 (+1.15%)
Market Cap
$1.93B
Shares
90.04M
Volume · Oct 26 24.51K Avg daily vol (56 sessions) 499.9K

Every disclosed holder of BRVE in one list: 13F institutions, Schedule 13D and 13G filers, insiders (Forms 3, 4 and 5) and registered funds, each from its own latest filing. Holders nest by CIK and SEC reporting links, never by name, and each is summed once.

Who Owns BRVE

13F quarter Sep 30, 2026

No chart: the summed disclosures exceed shares outstanding, so they are not parts of one whole.

Holder group Shares % Out
Institutional (13F) 10 0.00%
Insiders (Forms 3, 4, 5) 86,359,811 95.91%
13D/G-only blocks 4,976,457 5.53%
Remaining 1,297,309 -1.44%
Registered funds (N-PORT, not summed) 0 0.00%

Shares outstanding: 90,038,969, the issuer's latest cover-page count restated onto today's split basis.

Remaining is negative: the summed disclosures exceed shares outstanding, as when filings are dated at different times or holders that do not disclose their links count the same shares. It is flagged, not clipped.

13D/G-only counts each filer's latest 13D or 13G that no 13F report of the listing contains, that names no 13F filer and that no counted insider files. Funds are never summed: their shares sit inside their advisers' 13F reports.

Holders of BRVE

# Holder Shares
1
Forbion Growth Opportunities Fund III Cooperatief U.A.
Insider CIK 2050895 · Aug 7, 2026
10% Owner, issuer-wide
21,826,024
2
Chimovits Erez
Insider CIK 1706399 · Aug 7, 2026
Director, issuer-wide
12,175,159
3
ORBIMED ADVISORS LLC
13D CIK 1055951 · Registered investment adviser · Sep 8, 2026
Item 4 purpose: none of the classified purposes
not summed
12,175,159
3.1
ORBIMED ADVISORS LLC
Insider CIK 1055951 · Aug 7, 2026
10% Owner, issuer-wide
12,175,159
4
Agarwala Vineeta
Insider CIK 2003663 · Aug 7, 2026
Director, issuer-wide
10,232,420
5
AH Bio Fund IV, L.P.
13D CIK 1889476 · Unknown · Aug 7, 2026
Item 4 purpose: Passive investment
not summed
10,232,420
5.1
AH Bio Fund IV, L.P.
Insider CIK 1889476 · Aug 7, 2026
10% Owner, issuer-wide
10,232,420
6
Murdoch Travis
Insider CIK 1845681 · Aug 7, 2026
Director, CEO and President, issuer-wide
8,333,637
7
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Insider CIK 2080343 · Aug 7, 2026
10% Owner, issuer-wide
7,420,091
8
James N. Topper
13G CIK 1863769 · Unknown · Aug 7, 2026
Rule 13d-1(c), passive investor
4,976,457
9
Coloma Jason V
Insider CIK 1676170 · Aug 5, 2026
Director, Chief Executive Officer, issuer-wide
1,100,456
10
Malek David I
Insider CIK 2141639 · Aug 7, 2026
Director, issuer-wide
1,013,297
11
Viehbacher Christopher
Insider CIK 1774478 · Aug 7, 2026
Director, President and CEO, issuer-wide
759,857
12
Rickey James Paul
Insider CIK 1606243 · Aug 7, 2026
Chief Financial Officer, issuer-wide
703,575
13
Anderson Michele A.
Insider CIK 2141644 · Aug 7, 2026
Chief Development Officer, issuer-wide
332,161
14
Lubner David Charles
Insider CIK 1572000 · Aug 7, 2026
Director, issuer-wide
55,555
15
SBI Securities Co., Ltd.
13F CIK 1851815 · Non-US institution · Sep 30, 2026
10

Shares are restated onto today's split basis. Change compares each row with the same holder's previous filing in the same source; a dash means there is none to compare. Nested 13D/G, insider and fund rows are not summed, since a 13F report already holds them.

Key facts CIK 2131524 CUSIP 10567X101 13F (30d) 1 filings 1 filers Visit website Investor relations